CALIDI BIOTHERAPEUTICS INC(CLDI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CLDI CALIDI BIOTHERAPEUTICS INC

Market Closed 10-25 16:00:00 EDT

1.09

+0.25

+29.76%

盘后1.03

-0.06-5.50%

19:59 EDT

High1.23	Low0.7300	Vol6.31M
Open0.7900	D1 Closing0.8400	Amplitude59.52%
Mkt Cap10.15M	Tradable Cap9.95M	Total Shares9.31M
T/O6.53M	T/O Rate69.05%	Tradable Shares9.13M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"CLDI","market":"US","secType":"STK","nameCN":"CALIDI BIOTHERAPEUTICS INC","latestPrice":1.09,"timestamp":1729886400000,"preClose":0.84,"halted":0,"volume":6305679,"hourTrading":{"tag":"盘后","latestPrice":1.03,"preClose":1.09,"latestTime":"19:59 EDT","volume":2854564,"amount":3121025.56535,"timestamp":1729900793163},"delay":0,"floatShares":9131853,"shares":9310522,"eps":-7.172755,"marketStatus":"Market Closed","change":0.25,"latestTime":"10-25 16:00:00 EDT","open":0.79,"high":1.23,"low":0.73,"amount":6533998.8086394,"amplitude":0.595238,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-7.172755,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1730102400000},"marketStatusCode":7,"adr":0,"exchange":"AMEX","adjPreClose":0.84,"preHourTrading":{"tag":"盘前","latestPrice":0.7715,"preClose":0.84,"latestTime":"09:24 EDT","volume":42036,"amount":36384.2345784,"timestamp":1729862670332},"postHourTrading":{"tag":"盘后","latestPrice":1.03,"preClose":1.09,"latestTime":"19:59 EDT","volume":2854564,"amount":3121025.56535,"timestamp":1729900793163},"volumeRatio":15.842627268084353},"requestUrl":"/m/hq/s/CLDI","defaultTab":"news","newsList":[{"id":"2478933120","title":"Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV","url":"https://stock-news.laohu8.com/highlight/detail?id=2478933120","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478933120?lang=en_us&edition=fundamental","pubTime":"2024-10-25 21:00","pubTimestamp":1729861200,"startTime":"0","endTime":"0","summary":"ORLANDO, FL / ACCESSWIRE / October 25, 2024 / RedChip Companies will air interviews with Nexalin Technology, Inc.  and Calidi Biotherapeutics, Inc.  on the RedChip Small Stocks, Big Money show, a sponsored program on Bloomberg TV, this Saturday, October 26, at 7 p.m. Eastern Time . Bloomberg TV is available in an estimated 73 million homes across the U.S.Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin's products are believed to be non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/_CGqlr_T72W08fVAOQ9fAw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/e0cfc5cb7f676adb9179054efe7f38b8","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/_CGqlr_T72W08fVAOQ9fAw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/e0cfc5cb7f676adb9179054efe7f38b8"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nexalin-technology-calidi-biotherapeutics-interviews-130000229.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4581","BK4588","03160","BK4555","CLDI","TM","BK4561","ET","TV","NXL","AIRI","BK4187","BK4590","BK4144","BK4099","BK4139","NXLIW","BK4100","BK4585"],"gpt_icon":0},{"id":"2477381236","title":"Calidi Biotherapeutics to Present Data Supporting RTNova at Upcoming Scientific Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2477381236","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477381236?lang=en_us&edition=fundamental","pubTime":"2024-10-24 20:30","pubTimestamp":1729773000,"startTime":"0","endTime":"0","summary":"- RTNova, an innovative systemic antitumor enveloped virotherapy, unlocks new possibilities in cancer therapy. - RTNova addresses challenges posed by untargetable and untreatable metastatic diseases, offering a potential transformative solution with wide-ranging applications. SAN DIEGO, Oct. 24, 2024  -- Calidi Biotherapeutics Inc.  , a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies and viral vectors, will present data supporting RTNova , the company’s systemic antitumor virotherapy platform, at the International Oncolytic Virotherapy Conference  in Rotterdam, Netherlands, October 27-30, 2024, and at Immuno US 2024 in San Diego, October 28-30, 2024. In addition, a poster will be presented at the Society for Immunotherapy of Cancer  Annual Meeting in Houston, November 6-10, 2024.Leading the presentations will be Antonio F. Santidrian, Ph.D., Calidi’s Chief Scientific Officer, and Duong H. Nguyen, Ph.D., Calidi’s Senior Director of Tr","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/2aK7GW04qPybB7CII7CWkA--~B/aD0yNzM7dz04ODI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/7d704f48e72f79f78ddf2658e92deb06","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/2aK7GW04qPybB7CII7CWkA--~B/aD0yNzM7dz04ODI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/7d704f48e72f79f78ddf2658e92deb06"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/calidi-biotherapeutics-present-data-supporting-123000623.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4231","BK4080","SITC","CLDI"],"gpt_icon":0},{"id":"2477568110","title":"Calidi Biotherapeutics Shares Plunge After Pricing $2 Million Direct Offering, Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2477568110","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477568110?lang=en_us&edition=fundamental","pubTime":"2024-10-24 02:53","pubTimestamp":1729709584,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics (CLDI) shares were down 22% in recent trading on Wednesday after the company said it priced a registered direct offering and concurrent private placement.The biotechnology compa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","CLDI"],"gpt_icon":0},{"id":"2477353170","title":"Calidi Biotherapeutics stock tumbles on $2M securities offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2477353170","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477353170?lang=en_us&edition=fundamental","pubTime":"2024-10-23 21:30","pubTimestamp":1729690235,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics  shares fell over 10% Wednesday morning after the company priced an offering of 2.05M common shares at $1.00 per share. The clinical-stage biotechnology company also entered into a concurrent private placement to issue series E warrants to purchase up to 2.05M common shares and series F warrants to purchase up to 2.05M common shares. The series E warrants have an exercise price of $1.13 per share, while the series F warrants are exercisable at $1.13 per share. The gross proceeds from the offerings are expected to be approximately $2M. Calidi  intends to use the net proceeds for working capital, general corporate purposes and pre-clinical and clinical trials. Shares of the biotech firm were down more than 10% in premarket trading on Wednesday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4194797-calidi-biotherapeutics-tumbles-on-2m-direct-offering","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4139","CLDI"],"gpt_icon":0},{"id":"2477849935","title":"Calidi to sell 2.05M shares at $1.00 in registered direct offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2477849935","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477849935?lang=en_us&edition=fundamental","pubTime":"2024-10-23 20:35","pubTimestamp":1729686918,"startTime":"0","endTime":"0","summary":"Calidi (CLDI) Biotherapeutics has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/calidi-to-sell-2-05m-shares-at-1-00-in-registered-direct-offering?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/calidi-to-sell-2-05m-shares-at-1-00-in-registered-direct-offering?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CLDI","BK4139"],"gpt_icon":0},{"id":"2477169581","title":"Calidi Biotherapeutics Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2477169581","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477169581?lang=en_us&edition=fundamental","pubTime":"2024-10-23 20:31","pubTimestamp":1729686673,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241023:nTUA2TZLFX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLDI","BK4139"],"gpt_icon":0},{"id":"2477581157","title":"Press Release: Calidi Biotherapeutics Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2477581157","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477581157?lang=en_us&edition=fundamental","pubTime":"2024-10-23 20:31","pubTimestamp":1729686660,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement. SAN DIEGO, Oct. 23, 2024  -- Calidi Biotherapeutics, Inc.  , a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 2,050,000 shares of the Company's common stock at a price of $1.00 per share of common stock in a registered direct offering.The warrants described above are being offered in a private placement under Section 4 of the Securities Act of 1933, as amended , and Regulation D promulgated thereunder and, al","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI","BK4139"],"gpt_icon":0},{"id":"2476710212","title":"Nyse American to Commence Delisting Proceedings With Respect to the Warrants of Calidi Biotherapeutics, Inc. (Cldi Ws)","url":"https://stock-news.laohu8.com/highlight/detail?id=2476710212","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476710212?lang=en_us&edition=fundamental","pubTime":"2024-10-19 11:00","pubTimestamp":1729306802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241019:nTUA70DY0Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLDI","BK4139"],"gpt_icon":0},{"id":"2476271071","title":"Calidi Biotherapeutics Inc - Common Stock Trading to Continue on Nyse American","url":"https://stock-news.laohu8.com/highlight/detail?id=2476271071","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476271071?lang=en_us&edition=fundamental","pubTime":"2024-10-19 11:00","pubTimestamp":1729306802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241019:nTUA70DY0Q:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLDI","BK4139"],"gpt_icon":0},{"id":"2476748222","title":"NYSE American to Commence Delisting Proceedings with Respect to the Warrants of Calidi Biotherapeutics, Inc. (CLDI WS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2476748222","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476748222?lang=en_us&edition=fundamental","pubTime":"2024-10-19 11:00","pubTimestamp":1729306800,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Oct.  18, 2024  (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor v","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/19/2965784/0/en/NYSE-American-to-Commence-Delisting-Proceedings-with-Respect-to-the-Warrants-of-Calidi-Biotherapeutics-Inc-CLDI-WS.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI","BK4107","WS","NYSE","BK4139","BK4117","BK4006","AFG"],"gpt_icon":0},{"id":"2476487612","title":"Calidi Biotherapeutics: Nyse American to Commence Delisting Proceedings With Respect to Warrants of Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2476487612","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476487612?lang=en_us&edition=fundamental","pubTime":"2024-10-19 05:28","pubTimestamp":1729286885,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241018:nFWN3LU11L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLDI","BK4139"],"gpt_icon":0},{"id":"2476239219","title":"Calidi Biotherapeutics and Gorilla Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV","url":"https://stock-news.laohu8.com/highlight/detail?id=2476239219","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476239219?lang=en_us&edition=fundamental","pubTime":"2024-10-18 20:45","pubTimestamp":1729255500,"startTime":"0","endTime":"0","summary":"ORLANDO, FL / ACCESSWIRE / October 18, 2024 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc.  and Gorilla Technology Group Inc.  on the RedChip Small Stocks, Big Money show, a sponsored program on Bloomberg TV, this Saturday, October 19, at 7 p.m. Eastern Time . Bloomberg TV is available in an estimated 73 million homes across the U.S.Calidi Biotherapeutics  is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi's novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi's clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enh","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/_CGqlr_T72W08fVAOQ9fAw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/e0cfc5cb7f676adb9179054efe7f38b8","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/_CGqlr_T72W08fVAOQ9fAw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/e0cfc5cb7f676adb9179054efe7f38b8"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/calidi-biotherapeutics-gorilla-technology-interviews-124500350.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AIRI","BK4590","03160","GRRRW","BK4555","BK4561","BK4099","BK4023","ET","BK4585","BK4139","CLDI","BK4144","BK4588","BK4581","TV","BK4100","BK4187","GRRR","TM"],"gpt_icon":0},{"id":"2472670535","title":"Calidi Biotherapeutics files $25M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2472670535","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472670535?lang=en_us&edition=fundamental","pubTime":"2024-10-02 05:22","pubTimestamp":1727817723,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics (NYSE:CLDI) filed for $25M mixed securities shelf.\nThis prospectus is not an offer to sell.\nFiling","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4155272-calidi-biotherapeutics-files-25m-mixed-securities-shelf","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["CLDI","BK4139"],"gpt_icon":0},{"id":"2472453876","title":"Calidi Biotherapeutics Inc Files for Mixed Shelf Offering of up to $25 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2472453876","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472453876?lang=en_us&edition=fundamental","pubTime":"2024-10-02 05:07","pubTimestamp":1727816876,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241001:nFWN3LD1EU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLDI","BK4139"],"gpt_icon":0},{"id":"2471800868","title":"Calidi Biotherapeutics Says FDA Clears Phase 1b/2 Trial of CLD-101 in High-Grade Glioma","url":"https://stock-news.laohu8.com/highlight/detail?id=2471800868","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471800868?lang=en_us&edition=fundamental","pubTime":"2024-09-30 21:02","pubTimestamp":1727701337,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics  said Monday that the US Food and Drug Administration has cleared Northwestern University's investigational new drug application for the company's CLD-101 therapy, which uses stem cells to deliver engineered oncolytic adenoviruses.A phase 1b/2 trial of the investigational treatment is expected to begin late this year at the Northwestern University, Calidi said.The study will evaluate the safety of giving multiple doses of CLD-101 to patients with newly diagnosed high-grade glioma, according to the company.Shares of Calidi were down 4% in recent Monday premarket activity.Price: 1.1600, Change: -0.05, Percent Change: -4.13","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","CLDI"],"gpt_icon":0},{"id":"2471809016","title":"Calidi Biotherapeutics Inc - Phase 1B/2 Trial to Commence in Late 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2471809016","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471809016?lang=en_us&edition=fundamental","pubTime":"2024-09-30 20:00","pubTimestamp":1727697602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240930:nTUA4PLGWX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLDI","BK4139"],"gpt_icon":0},{"id":"2471090288","title":"Calidi Biotherapeutics Inc - Phase 1B/2 Study to Evaluate Safety and Feasibility of Cld-101","url":"https://stock-news.laohu8.com/highlight/detail?id=2471090288","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471090288?lang=en_us&edition=fundamental","pubTime":"2024-09-30 20:00","pubTimestamp":1727697602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240930:nTUA4PLGWX:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLDI"],"gpt_icon":0},{"id":"2471037809","title":"Calidi Biotherapeutics Announces FDA Clearance of the NorthWestern University Ind Application for Cld-101 Clinical Trial in High-Grade Glioma","url":"https://stock-news.laohu8.com/highlight/detail?id=2471037809","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471037809?lang=en_us&edition=fundamental","pubTime":"2024-09-30 20:00","pubTimestamp":1727697602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240930:nTUA4PLGWX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLDI"],"gpt_icon":0},{"id":"2466252985","title":"Funicular Funds, Lp Reports 9.99% Passive Stake in Calidi Biotherapeutics as of September 4- SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2466252985","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466252985?lang=en_us&edition=fundamental","pubTime":"2024-09-12 04:06","pubTimestamp":1726085164,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240911:nFWN3KT0T2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLDI"],"gpt_icon":0},{"id":"2461268374","title":"Calidi Biotherapeutics Unveils Redtail Biopharma Subsidiary","url":"https://stock-news.laohu8.com/highlight/detail?id=2461268374","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2461268374?lang=en_us&edition=fundamental","pubTime":"2024-08-23 05:49","pubTimestamp":1724363345,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics (CLDI) has provided an announcement. Calidi Biotherapeutics, Inc. has announced the launch of its new subsidiary, Redtail Bi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/calidi-biotherapeutics-unveils-redtail-biopharma-subsidiary?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/calidi-biotherapeutics-unveils-redtail-biopharma-subsidiary?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CLDI"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.calidibio.com","stockEarnings":[{"period":"1week","weight":-0.1066},{"period":"1month","weight":-0.0522},{"period":"3month","weight":-0.3101},{"period":"6month","weight":-0.3217},{"period":"1year","weight":-0.9564},{"period":"ytd","weight":-0.9278}],"compareEarnings":[{"period":"1week","weight":-0.0095},{"period":"1month","weight":0.0158},{"period":"3month","weight":0.0636},{"period":"6month","weight":0.1393},{"period":"1year","weight":0.4036},{"period":"ytd","weight":0.2182}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":-0.153431},{"month":2,"riseRate":0.666667,"avgChangeRate":-0.08358},{"month":3,"riseRate":0.666667,"avgChangeRate":-0.016188},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.217615},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.004339},{"month":6,"riseRate":1,"avgChangeRate":0.021452},{"month":7,"riseRate":0.666667,"avgChangeRate":-0.069725},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.132691},{"month":9,"riseRate":0,"avgChangeRate":-0.2176},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.12602},{"month":11,"riseRate":0.5,"avgChangeRate":-0.011319},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.091347}],"exchange":"AMEX","name":"CALIDI BIOTHERAPEUTICS INC","nameEN":"CALIDI BIOTHERAPEUTICS INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CALIDI BIOTHERAPEUTICS INC(CLDI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CALIDI BIOTHERAPEUTICS INC(CLDI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CALIDI BIOTHERAPEUTICS INC,CLDI,CALIDI BIOTHERAPEUTICS INC股票,CALIDI BIOTHERAPEUTICS INC股票老虎,CALIDI BIOTHERAPEUTICS INC股票老虎国际,CALIDI BIOTHERAPEUTICS INC行情,CALIDI BIOTHERAPEUTICS INC股票行情,CALIDI BIOTHERAPEUTICS INC股价,CALIDI BIOTHERAPEUTICS INC股市,CALIDI BIOTHERAPEUTICS INC股票价格,CALIDI BIOTHERAPEUTICS INC股票交易,CALIDI BIOTHERAPEUTICS INC股票购买,CALIDI BIOTHERAPEUTICS INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CALIDI BIOTHERAPEUTICS INC(CLDI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CALIDI BIOTHERAPEUTICS INC(CLDI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction